Nautilus Biotechnology (NASDAQ:NAUT) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Nautilus Biotechnology (NASDAQ:NAUT) released its quarterly earnings results on Thursday. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03, FiscalAI reports.

Here are the key takeaways from Nautilus Biotechnology’s conference call:

• Nautilus launched its Iterative Mapping Early Access Program in January (starting with the tau proteoform assay), with initial customer feedback described as encouraging but not expected to generate material revenue in 2026.
• The company publicly unveiled the Voyager instrument at US HUPO and reiterated a commercialization timeline of beta deployments, opening pre-orders in late 2026 and customer installations beginning in early 2027, which management expects will drive the recurring consumables revenue ramp.
• Technical progress and external validation advanced in Q4 — the broad-scale assay configuration change produced encouraging initial data, collaborators (Buck Institute, Allen Institute) reported novel tau proteoform biology, and an MJFF-funded $1.2M award to Nautilus will develop an alpha‑synuclein proteoform assay, signaling expansion beyond tau toward additional disease targets.
• Financially, Nautilus ended Q4 with $156.1M in cash and investments, reduced 2025 cash burn to $50.2M, expects 2026 cash burn of $65M–$70M with operating expense growth of ~15%–20%, and projects a cash runway extending through 2027.

Nautilus Biotechnology Trading Down 2.1%

NASDAQ:NAUT traded down $0.05 during midday trading on Friday, reaching $2.37. The company had a trading volume of 68,119 shares, compared to its average volume of 218,988. The firm has a market capitalization of $299.35 million, a price-to-earnings ratio of -4.74 and a beta of 1.49. The stock’s fifty day simple moving average is $2.15 and its 200-day simple moving average is $1.56. Nautilus Biotechnology has a 12-month low of $0.62 and a 12-month high of $3.08.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on NAUT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Thursday, January 22nd. Guggenheim increased their price objective on shares of Nautilus Biotechnology from $2.50 to $4.00 and gave the company a “buy” rating in a report on Friday. Finally, Wall Street Zen upgraded shares of Nautilus Biotechnology from a “sell” rating to a “hold” rating in a research report on Tuesday, November 18th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $4.00.

Institutional Trading of Nautilus Biotechnology

A number of hedge funds have recently added to or reduced their stakes in NAUT. Marshall Wace LLP acquired a new position in shares of Nautilus Biotechnology in the 4th quarter valued at $228,000. Jane Street Group LLC grew its stake in Nautilus Biotechnology by 304.1% during the 2nd quarter. Jane Street Group LLC now owns 290,369 shares of the company’s stock worth $210,000 after buying an additional 218,512 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in Nautilus Biotechnology in the 4th quarter valued at approximately $204,000. Jacobs Levy Equity Management Inc. acquired a new stake in Nautilus Biotechnology in the first quarter worth approximately $194,000. Finally, Squarepoint Ops LLC boosted its holdings in Nautilus Biotechnology by 29.5% during the third quarter. Squarepoint Ops LLC now owns 131,827 shares of the company’s stock worth $111,000 after buying an additional 30,005 shares in the last quarter. 50.71% of the stock is owned by institutional investors and hedge funds.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.